Clinical Trial Update: A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update comparing Sativex with placebo (both with dose-intensive temozolomide) in recurrent glioblastoma; phases 1 and 2 have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED